The benefits of direct-to-patient supply to mitigate risk in decentralized studies.

The reasons behind implementing a multi-segment Phase 2 study and implications on kit design.

Proactive Clinical Supply Planning-Early to Late Phase

Management of advanced supply chain CMC collaborators and CDMO partners.

The importance of project management, and key elements to consider to help keep trials on time and budget.

Explore key aspects of Japan’s regulatory environment to consider when developing a clinical supply plan and associated timelines.

Learn how unconventional trials impact the supply chain and the role a CDMO can play in facilitating these studies.

Learn what clinical sponsors should look for when assessing integrated services and potential providers.

How adopting the decentralized trial approach introduces new challenges for companies hoping to ramp up an early phase trial or keep later stage studies going during the pandemic.

The global pandemic provides an opportunity for the further decentralization of clinical trials, with direct-to-patient protocols reducing or eliminating the need for patients to travel to clinical sites and potentially expose themselves and others to a risk of infection.​